LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients
- 1 May 2003
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 23 (5), 853-858
- https://doi.org/10.1161/01.atv.0000066131.01313.eb
Abstract
Objective— Triglyceride-rich lipoproteins that contain apolipoprotein CIII (apoCIII) are prominent in diabetic dyslipidemia. We hypothesized that these lipoproteins increase coronary disease risk in diabetic patients beyond that caused by standard lipid risk factors. Methods and Results— Diabetic patients with previous myocardial infarction were followed for 5 years, and 121 who had a recurrent coronary event were matched to 121 who did not. VLDL and LDL that contained or did not contain apoCIII (CIII+ or CIII−) were prepared by immunoaffinity chromatography and ultracentrifugation. IDL was included in the LDL fraction. LDL CIII+, rich in cholesterol and triglyceride, was the strongest predictor of coronary events (relative risk [RR] 6.6, P P =0.07). The increased risk associated with LDL CIII+ was unaffected by adjustment for plasma lipids, apoB, non-HDL cholesterol, or the other VLDL and LDL types. For VLDL CIII+, RR 0.5, P =0.07; for VLDL CIII−, RR 2.3, P =0.046. The presence of apolipoprotein E with CIII on VLDL and LDL did not affect risk. Conclusions— LDL with apoCIII strongly predicts coronary events in diabetic patients independently of other lipids and may be an atherogenic remnant of triglyceride-rich VLDL metabolism.Keywords
This publication has 23 references indexed in Scilit:
- Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)BMJ, 1998
- Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.JCI Insight, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and compositionBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Very-fast ultracentrifugation of human plasma lipoproteins: influence of the centrifugal field on lipoprotein compositionClinica Chimica Acta; International Journal of Clinical Chemistry, 1994
- Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and EAtherosclerosis, 1990
- INTERMEDIATE-DENSITY LIPOPROTEINS AND PROGRESSION OF CORONARY ARTERY DISEASE IN HYPERCHOLESTEROLAEMIC MENThe Lancet, 1987
- Lipoprotein lipase in diabetesDiabetes/Metabolism Research and Reviews, 1987
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.JCI Insight, 1986
- Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study.BMJ, 1983